FDA Under Fire to block documents on the safety of puberty blockers for children

America First Legal (AFL) continued the Food and Drug Administration on Friday to obtain files from the Biden era linked to the internal government councils for the recommended use of puberty blockers for children.

The legal group aligned by Trump previously discovered the communications of the former administration through a request from the Freedom of Information Act (FoIA), which would have shown that the FDA knew that these drugs increased mental health risk but still recommended to approve them for children.

Following these discovery communications, the AFL followed a separate foia requiring documents specifically concerning the internal directives of the FDA for the outsourcing use of these drugs. Despite the recognition of the Federal Information Request, the FDA has not cooperated and the deadline to produce documents is increasing.

Democratic states continue the Trump administrator at the end of sex change surgeries for minors

“The Biden administration has pushed sex treatments on American children. Now it’s time to exhibit what officials really knew,” said AFL Will Scoinos lawyer.

America First Legal, a group aligned by Trump, continued files from the Biden era linked to its recommended guidelines on puberty blockers for gender dysphoric children. (Getty Images)

Similar to AFL’s current Foia request, the group had to engage in disputes to oblige the release of the first set of documents.

But, finally, documents were published which seemed to show that the division of general endocrinology of the Biden era at the FDA has recommended that the agency approves puberty blockers for children despite knowledge that there were negative impacts associated with them, such as an increased depression, suicidality and risks of seizure.

“It is certainly necessary that these drugs be approved for gender transition,” said an FDA official of the agency’s endocrinology division in an e-mail discovered by AFL. In the same communications, the FDA official also explicitly declares that studies have found “an increased risk of depression and suicidality, as well as the increase in the risk of crisis”.

These results have also been confirmed by other studies.

Protesters for and against gender surgery for transgender minors demonstrate outside the Supreme Court on December 4, 2024 in Washington, DC (AP photo / Jose Luis Magana, file)

Researchers from the University of Texas sample 107,583 patients aged 18 and over who suffered from gender dysphoria, including some who have undergone gender surgery, and have concluded that “gender sensitive mental support … Taking post-surgical psychological risks” is a “necessity”.

Progressive trapped in the “disinformation bubble” on the treatments of transgender youth, the admission of the Atlantic admits

Men who underwent surgery had 25% depression rates compared to men without surgery, who had rates slightly less than 12%. Anxiety rates among this group were 12.8% against 2.6%.

The same differences were also observed between women. Those who were surgical had depression rates of 22.9% against 14.6% in the non -surgical group. Women who underwent surgery also had an anxiety rate of 10.5% against 7.1% for girls who had not been operated.

Medical syringes are juxtaposed above the FDA logo. (Jakub Porzycki / Nurphoto via Getty Images)

Click here to obtain the Fox News app

Fox News Digital contacted the FDA to comment but did not immediately receive an answer.

Melissa Rudy and Michael Dorgan from Fox News contributed to this report